Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab and golimumab combination therapy in moderately to severely active ulcerative colitis
NL-OMON59920Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing JNJ-78934804 combination therapy, Guselkumab monotherapy and Golimumab monotherapy (3 arms). Primary endpoint: Clinical remission at Week 48. Started Mar 2023; status: active, not recruiting.
02
Drugs
guselkumabgolimumabguselkumab + golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON59920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59920.